Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SITC 2021 | ARTACUS: exploring vusolimogene oderparepvec for the treatment of cancer patients with CSCC

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, outlines the Phase I ARTACUS (NCT04349436) trial in patients with cutaneous squamous cell carcinoma (CSCC). The ongoing Phase I trial investigates the oncolytic virus vusolimogene oderparepvec for the treatment of patients who have developed CSCC due to the suppression of their immune system following a solid organ transplant. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.